Xolid Infusion (200mg & 400mg & 600mg) - Intravenous Oxazolidinone Antibacterial Solution

Product Overview

Xolid Infusion is a broad-spectrum, synthetic oxazolidinone parenteral formulation containing Linezolid (2mg/ml in an isotonic aqueous vehicle). Formulated for slow Intravenous (IV) infusion, Xolid provides immediate 100% systemic bioavailability for hospitalized or critically ill patients unable to take oral medications. It is indicated for the treatment of severe, complicated Gram-positive bacterial infections, including Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococcus faecium (VRE), nosocomial and community-acquired pneumonia, and complicated skin and skin structure infections (cSSSI).

Key Benefits

\n
• \n

  Parenteral Critical Care Solution: Delivers immediate, predictable blood concentrations required for severe inpatient Gram-positive infections.

  \n
\n
• \n

  Gold-Standard VRE & MRSA Coverage: Highly effective against multi-drug resistant pathogens where traditional antibiotics like penicillins or cephalosporins fail.

  \n
\n
• \n

  Early-Stage Protein Synthesis Inhibition: Features a unique molecular target that minimizes cross-resistance with other major antibiotic classes.

  \n
\n
• \n

  Ready-to-Use Premixed Infusion: Supplied in a pre-formulated isotonic infusion bag/bottle, reducing clinical preparation time and contamination risk.

  \n
\n
• \n

  Smooth Transition to Oral Therapy: Demonstrates bioequivalent exposure that allows a seamless switch to oral Xolid tablets or suspension once the patient stabilizes.

  \n
\n

How It Works

Xolid Infusion (Linezolid) exerts its antibacterial action by selectively binding to the 23S ribosomal RNA of the 50S subunit on the bacterial ribosome. This action prevents the assembly of the functional 70S initiation complex, which is essential for translating messenger RNA (mRNA) into vital bacterial proteins. By blocking protein synthesis at this early stage, Xolid halts bacterial replication, reduces toxin production, and eradicates multi-drug resistant Gram-positive pathogens.

WooCommerce Attribute / Variation Details

Variation 1: XOLID INFUSION 200MG (200mg/100ml)

\n
• \n

  SKU: XOL-INF-200

  \n
\n
• \n

  Short Description: Designed for pediatric intravenous dosing, weight-adjusted inpatient regimens, and step-down dose titration.

  \n
\n
• \n

  Key Active Ingredient: Linezolid — 200mg per 100ml ready-to-use infusion solution (2mg/ml).

  \n
\n
• \n

  Target Indications: Pediatric MRSA/VRE infections, weight-based pediatric pneumonia management, and targeted inpatient care.

  \n
\n
• \n

  Standard Dosing: Administered via slow IV infusion over 30 to 120 minutes every 8 to 12 hours based on pediatric weight guidelines (typically 10mg/kg).

  \n
\n

Variation 2: XOLID INFUSION 400MG (400mg/200ml)

\n
• \n

  SKU: XOL-INF-400

  \n
\n
• \n

  Short Description: Formulated for adolescent dosing, adult weight-adjusted parenteral regimens, and moderate-to-severe inpatient infections.

  \n
\n
• \n

  Key Active Ingredient: Linezolid — 400mg per 200ml ready-to-use infusion solution (2mg/ml).

  \n
\n
• \n

  Target Indications: Nosocomial pneumonia, complicated skin and soft tissue structure infections, VRE bacteremia, and MRSA sepsis.

  \n
\n
• \n

  Standard Dosing: Administered via slow IV infusion over 30 to 120 minutes every 12 hours as prescribed by an attending infectious disease specialist.

  \n
\n

General Product Details (Shared across variations)

Key Active Ingredients

\n
• \n

  Linezolid (200mg / 400mg per infusion bottle): Synthetic parenteral oxazolidinone antibacterial agent that blocks bacterial 70S ribosomal initiation.

  \n
\n

Directions for Use

\n
1. \n

   Administration Route: Strictly for Intravenous (IV) Infusion. Do NOT administer via intramuscular or intravenous push/bolus injection.

   \n
\n
2. \n

   Infusion Rate: Administer the premixed infusion solution slowly over a period of 30 to 120 minutes.

   \n
\n
3. \n

   Compatibility: Do not add supplementary medications to the infusion solution. If the same intravenous line is used for sequential infusion of other drugs, flush the line before and after Xolid infusion with a compatible solution (e.g., 0.9% Sodium Chloride or 5% Dextrose).

   \n
\n
4. \n

   Professional Healthcare Use: Must be administered exclusively by qualified healthcare personnel in a hospital, clinic, or emergency setting.

   \n
\n

Precautions

\n
• \n

  Prescription-Only Parenteral: For inpatient hospital and critical care administration only; strictly prohibited for self-administration.

  \n
\n
• \n

  Reversible MAO Inhibition Warning: Linezolid is a reversible, non-selective Monoamine Oxidase (MAO) inhibitor. Avoid co-administration with serotonergic drugs (SSRIs, SNRIs, tricyclic antidepressants) to prevent serotonin syndrome.

  \n
\n
• \n

  Hematologic Monitoring: Reversible myelosuppression (anemia, leukopenia, pancytopenia, and thrombocytopenia) may occur, especially with therapy exceeding 14 days. Monitor complete blood counts (CBC) weekly.

  \n
\n
• \n

  Neuropathy Risk: Peripheral and optic neuropathy have been reported primarily in patients treated for longer than 28 days.

  \n
\n
• \n

  Consult an attending physician before use during pregnancy or lactation.

  \n
\n
• \n

  Keep out of reach of children.

  \n
\n

Storage Instructions

Store in a cool, dry place below 30°C. Protect from direct sunlight, excessive heat, and freezing. Retain in its protective overwrap/carton until administration. Inspect for clarity and absence of particulate matter prior to use.

Manufacturer Information

Formulated and manufactured in strict compliance with international pharmaceutical quality standards, committed to advancing parenteral anti-infective therapies that combat multi-drug resistant bacterial pathogens and support critical care recovery.